SAN FRANCISCO, Oct. 22, 2012 /PRNewswire/ -- Medizone International (MZEI:OB MZEI:QB), a leading-edge disinfection technology company and Transformix Engineering, a specialty engineering and manufacturing company, today jointly announce a new partnership agreement to manufacture Medizone's AsepticSure hospital disinfection technology.
Medizone International CEO Edwin Marshall commented on the partnership agreement: "Quality Control has been – and will always be – a major priority in the AsepticSure manufacturing process. With its outstanding reputation among our core market, long-proven commitment to customer satisfaction and a client list boasting names like DuPont, 3M, P&G, Pfizer, GE and Sandvik, Transformix clearly possesses the ability to satisfy our stringent QC and on-time-on-budget delivery requirements.
"As a result of the problems encountered with our first manufacturing partner we sought to up the ante in every area of the manufacturing process when deciding to switch manufacturers. To that end, Transformix possesses a level of professionalism, technical know-how, depth of engineering skills, state-of-the-art plant, customer support, favorable cost structures and a commitment to the time and cost-efficient requirements of a commercial enterprise rarely seen. In short, we're delighted to partner with them."
Marshall closed by saying, "Delivery of the first AsepticSure systems to be built by Transformix is anticipated this December. With a successful delivery of the first order, we then expect to ramp up production in order to meet estimated demand for the AsepticSure system for Q1 2013 deliveries."
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com
SOURCE Medizone International, Inc.